Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
GlucoTrack, Inc. (IGAP)
|
Add to portfolio |
|
|
|
| Price: |
$4.51
| | Metrics |
| OS: |
20.9
|
M
| |
54
|
% ROE
|
| Market cap: |
$94.1
|
M
| |
|
|
|
Net cash:
|
$8.77
|
M
| |
$0.42
|
per share
|
|
EV:
|
$85.4
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($4.7)
|
M
| |
|
|
|
EBIT
|
($4.7)
|
M
| |
|
|
| EPS |
$0.29
| |
15.4
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.8 | 0.2 | 0.0 | 21.7 | 0.6 | 0.1 |
| Revenue growth | | -100.0% | 261.2% | 380.0% | -99.8% | 3454.3% | 327.3% | 139.5% |
| Cost of goods sold | 0.0 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 21.7 | 0.6 | 0.1 |
| Gross margin | | | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | | | 3.4 | 2.5 |
| Sales and marketing | | 0.1 | 0.4 | 0.6 | 1.1 | 1.5 | | |
| Research and development | 2.0 | 1.8 | 1.5 | 1.6 | 3.0 | 3.2 | 2.9 | 2.3 |
| General and administrative | 2.5 | 2.1 | 1.2 | 1.5 | 2.5 | 6.4 | 2.3 | 1.4 |
| EBIT | -4.4 | -4.0 | -3.1 | -3.5 | -6.5 | 10.6 | -5.3 | -4.7 |
| EBIT margin | | | -415.4% | -1679.2% | -15035.4% | 48.6% | -868.8% | -3251.7% |
| Pre-tax income | 4.4 | 4.1 | 2.7 | -3.5 | -6.7 | -10.3 | -5.4 | -5.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -20.7 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 200.0% | 0.0% | 0.0% |
| Net income | 4.4 | 4.1 | 2.7 | -3.5 | -6.7 | 10.3 | -5.4 | -5.8 |
| Net margin | | | 357.6% | -1684.3% | -15442.0% | 47.5% | -884.4% | -4080.7% |
| |
| Diluted EPS | $0.29 | $0.26 | $0.18 | ($0.02) | ($0.80) | $1.64 | ($0.93) | ($1.07) |
| Shares outstanding (diluted) | 15.5 | 15.5 | 15.1 | 154.9 | 8.4 | 6.3 | 5.8 | 5.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|